Print

Laquinimod presentations at ECTRIMS

2009-09-08

To read the complete press release, please see www.tevapharm.com.
For further information, please contact:
Tomas Leanderson, President & CEO
Tel: +46 46 19 20 95
Göran Forsberg, VP Investor Relations & Business Development
Tel: +46 (0) 46 19 11 54
About Active Biotech
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, primarily of renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex(TM) for RA. Please visit www.activebiotech.com for more information.
Active Biotech AB
PO Box 724, SE-220 07 Lund
Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00
Active Biotech is required under the Securities Markets Act to make the information in this press release public. The information was submitted for publication at4:15 p.m. CET on September 8, 2009.

pdf



Back